AccuMetab™ Rat CYP2D18 Enzyme, Catalytically Active

CAT#: ITS-0426-YL59
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Rat CYP2D18 for reliable preclinical Phase I ADME profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Operating alongside other CYP2D orthologs, CYP2D18 contributes to the complex, multi-isoform Phase I metabolism seen in rodents. ADME profiling against this enzyme helps de-convolute species-specific drug clearance pathways and prevents misinterpretation of in vivo rat data.
Key Features
Complementary rat Phase I multienzyme pathway; Prevents misinterpretation of rat PK data; Pre-coupled with rat NADPH reductase; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Preclinical Species Comparison
Research Areas
ADME; Preclinical Toxicology
Species
Rat
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
1 nmol
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry